Stock Data
$0.21 (0.12%)
Asset Type
N/A
Exchange
N/A
Currency
N/A
Country
N/A
Sector
N/A
Industry
N/A
Becton Dickinson & Company, headquartered in Franklin Lakes, New Jersey, is a global leader in developing, manufacturing, and selling a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its offerings support healthcare institutions, physicians, life science researchers, and the pharmaceutical industry. The company operates across three main segments: BD Medical, focusing on products for IV therapy and medication management; BD Life Sciences, providing tools for blood collection and diagnostics; and BD Interventional, offering surgical and critical care products. Founded in 1897, it plays a crucial role in advancing medical discovery and care.
Management lifted the low end of full-year adjusted EPS guidance to a $12.62 to $12.72 range after the first full quarter as a standalone MedTech company, following February's Biosciences spin-off, landed ahead on both lines. GLP-1 demand for the Vystra injection pen drove the gain, with buybacks continuing.
Becton Dickinson reports at 6:30 AM ET, well before the open, so the guidance update and any fresh detail on the diagnostics separation hit while most investors are still asleep. At a $42.4 billion market cap, the full-year outlook matters more than the quarter itself.
89 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
